Antengene Partners with UCB for Global License of ATG-201 T-Cell Engager Targeting Autoimmune Disorders

Antengene Teams Up with UCB for ATG-201 License

Antengene Corporation Limited has entered into a significant global licensing agreement with UCB, granting the latter exclusive rights to develop, manufacture, and commercialize ATG-201. This innovative bispecific T-cell engager (TCE) is designed to target B cell-related autoimmune diseases, offering a promising therapeutic option as immunology continues to advance.

Overview of the Agreement

Under the terms of the agreement, Antengene will receive an initial upfront payment totaling USD 80 million, which includes $60 million at the outset followed by $20 million upon the achievement of certain development milestones. Additionally, the company is eligible for over USD 1.1 billion in potential success-based milestone payments and tiered royalties from future net sales of ATG-201.

The strategic collaboration emphasizes the unique capabilities of Antengene's AnTenGager™ platform, designed for developing next-generation T-cell engagers that can address various conditions beyond just autoimmune diseases. As part of this partnership, nine products still remain under this research and development pipeline, promoting long-term innovation in therapeutic options.

The Innovative Approach of ATG-201

ATG-201 is a bispecific TCE that targets CD19-expressing B cells, employing advanced steric hindrance masking technology to mitigate side effects while effectively eliminating these cells. This therapeutic approach not only has the potential for treating B cell-driven disorders but also aims to leverage the body’s immune system to enhance precision in therapy while reducing the risks associated with cytokine release syndrome (CRS).

Antengene plans to initiate clinical trial applications in China and Australia within the first quarter of 2026, with the first phase of human studies scheduled in these regions before transitioning further development efforts to UCB. This planned progression demonstrates the ambition of both companies to expedite the journey of ATG-201 from concept to market.

Expert Insights on the Collaboration

Dr. Jay Mei, Founder, Chairman, and CEO of Antengene, expressed enthusiasm regarding the partnership, highlighting the synergies between Antengene's innovative platform and UCB's proven expertise in immunology. He stated, "Our collaboration with UCB emphasizes our commitment to efficiently accelerate the development of ATG-201 on a global scale."

Furthermore, Alistair Henry, Chief Scientific Officer at UCB, noted the importance of this collaboration in expanding UCB's portfolio in immunology, remarking, "Our partnership with Antengene and access to their cutting-edge technology complements our ongoing ambitions in the field of biologics. This will drive forward our goal to lead innovations targeting immunological diseases."

Future Developments and Milestones

The newly forged collaboration is aimed not only at enhancing patient outcomes through innovative treatments but also at creating a robust commercial landscape for T-cell engagers in the market. UCB's commitment to combining monoclonal antibodies with novel biologics may provide pathways for future advancements in the treatment of various conditions.

As Antengene prepares to provide further details through a conference call scheduled for 9:00 a.m. HKT on March 4, 2026, stakeholders are eager to see the progress in the development pipeline and next steps for ATG-201.

In summary, this licensing agreement represents a significant step forward in immunotherapy for autoimmune diseases, paving the way for future innovations that may foster better outcomes for patients globally.